Purpura, Schoenlein-Henoch Clinical Trial
Official title:
Research on the Blood- Cooling - Toxin - Removing - Stasis - Dispersing Protocol Evaluation of Hench-schonlein Purpura
Due to high incidence of renal damage by Hench-schonlein Purpura(HSP) is the key to affect prognosis, this project moves the research emphasis forward in line with the idea of "prevention of progress of disease", Which concerns on Traditional Chinese Medicine(TCM) clinical research scheme evaluation of HSP, evaluates the renal damage and disease recurrence as the end event, and comes to the evaluation through the comparative study that the vantage point of the scheme of syndrome differentiation and treatment in detoxification, cooling blood and removing blood stasis to the conventional treatments can reduce kidney damage and recurrence rate.
Target:Optimize the TCM scheme of syndrome differentiation and treatment of HSP in line with
the idea of blood- Cooling - Toxin - Removing - Stasis - Dispersing under the path of
combination between disease differentiation and syndrome differentiation, and regards
reducing the rate of the recurrence of HSP and kidney damage as the end point of evaluation
indexes, to evaluate the clinical efficacy of the scheme scientifically. Main research
contents: Retrospective case investigation, analysis and research on literature, research on
clinical assessment of the scheme of syndrome differentiation and treatment. Methods:With a
series of compounds as the main interference factors, choosing the sample estimation of
superiority design and adopting the test methods of randomized, double-blind,
placebo-controlled to carry out the research of multicenter clinical efficacy evaluation.
It summarizes the advantages and rules of syndrome differentiation and treatment in TCM by
means of the comparative study, which provides technical guidelines for the industry and
sets an example to summarize the key common technology of clinical research, and also
improves the evaluation level of TCM clinical research and efficacy.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00006055 -
Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases
|
N/A | |
Completed |
NCT04387942 -
The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 in Children With Henoch-schönlein Purpura
|
N/A | |
Completed |
NCT00425724 -
HSP-glomerulonephritis Trial: MP vs CyA
|
Phase 4 | |
Recruiting |
NCT01610830 -
Identification of Biomarkers Predictive of Worse Prognosis in Henoch Schonlein Purpura
|
N/A |